The Immune Tolerance Network at 10 years: tolerance research at the bedside.

The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol (2012) 3.97

Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science (2014) 2.95

Engineering antigens for in situ erythrocyte binding induces T-cell deletion. Proc Natl Acad Sci U S A (2012) 1.01

Nonviral-mediated hepatic expression of IGF-I increases Treg levels and suppresses autoimmune diabetes in mice. Diabetes (2012) 0.89

Tolerogenic therapies in transplantation. Front Immunol (2012) 0.88

The battle against immunopathology: infectious tolerance mediated by regulatory T cells. Cell Mol Life Sci (2011) 0.87

MHC-derived allopeptide activates TCR-biased CD8+ Tregs and suppresses organ rejection. J Clin Invest (2014) 0.83

Anti-CD3ε mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: therapeutic implications. Blood (2012) 0.80

Evaluation of Candidate Biomarkers of Type 1 Diabetes via the Core for Assay Validation. Biomark Insights (2015) 0.78

Ancillary study management systems: a review of needs. BMC Med Inform Decis Mak (2013) 0.76

The place of immunotherapy in the management of HCV-induced vasculitis: an update. Clin Dev Immunol (2012) 0.76

Gene/cell therapy approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-linked syndrome. Curr Gene Ther (2014) 0.76

Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth. Diabetes Technol Ther (2013) 0.76

Actively acquired tolerance of foreign cells. Nature (1953) 19.82

International trial of the Edmonton protocol for islet transplantation. N Engl J Med (2006) 13.43

Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 11.05

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84

HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med (2008) 7.42

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity (2008) 6.08

Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med (1999) 5.46

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature (2002) 5.24

Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol (2006) 4.23

Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest (2010) 3.59

Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest (2010) 3.41

Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant (2006) 3.34

Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med (2006) 3.25

Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy. J Allergy Clin Immunol (2008) 2.87

The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med (1990) 2.35

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol (2009) 2.30

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 2.06

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol (2005) 1.99

Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A (2007) 1.90

Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A (2008) 1.83

Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med (2009) 1.76

Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes (2002) 1.61

T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev (2003) 1.57

Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes (2006) 1.49

Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant (2002) 1.38

Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol (2002) 1.28

B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans. Am J Transplant (2009) 1.27

Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus (2004) 1.22

Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant (2003) 1.21

Use of HLA class II tetramers in tracking antigen-specific T cells and mapping T-cell epitopes. Methods (2003) 1.18

In vivo biotinylation of the major histocompatibility complex (MHC) class II/peptide complex by coexpression of BirA enzyme for the generation of MHC class II/tetramers. Hum Immunol (2004) 1.17

T cell co-stimulation and in vivo tolerance. Curr Opin Immunol (1993) 1.12

CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology (2008) 1.08

CD103 mRNA levels in urinary cells predict acute rejection of renal allografts. Transplantation (2003) 1.07

Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol (2007) 1.06

The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods (2006) 1.03

A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1. Clin Immunol (2007) 1.03

Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am J Transplant (2009) 1.00

Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/perforin lytic pathway, is hyperexpressed during acute rejection of renal allografts. Transplantation (2003) 0.96

The immune tolerance network--an NIH/JDF-supported initiative to bring tolerance research into the clinic: a major new resource for clinical immunologists. Clin Immunol (2000) 0.93

Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after Thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine. Transpl Immunol (2010) 0.87

Frontiers in nephrology: immune tolerance to allografts in humans. J Am Soc Nephrol (2007) 0.85

Identification of tolerant recipients following liver transplantation. Int Immunopharmacol (2010) 0.81

International trial of the Edmonton protocol for islet transplantation. N Engl J Med (2006) 13.43

Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 11.05

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04

Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med (2007) 6.61

Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol (2007) 5.99

Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med (2013) 5.67

Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood (2010) 4.28

The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20

Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med (2003) 4.12

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum (2012) 4.01

Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest (2010) 3.59

Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet (2009) 3.33

Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum (2006) 3.29

Genetics of type 1A diabetes. N Engl J Med (2009) 3.18

Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A (2006) 3.13

B-lymphocyte contributions to human autoimmune disease. Immunol Rev (2008) 2.89

Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol (2004) 2.79

De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells. Proc Natl Acad Sci U S A (2005) 2.57

Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol (2004) 2.54

The cytokines interleukin 27 and interferon-γ promote distinct Treg cell populations required to limit infection-induced pathology. Immunity (2012) 2.52

Distinct effects of STAT5 activation on CD4+ and CD8+ T cell homeostasis: development of CD4+CD25+ regulatory T cells versus CD8+ memory T cells. J Immunol (2003) 2.47

TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med (2006) 2.44

TRAF6 is a critical factor for dendritic cell maturation and development. Immunity (2003) 2.36

Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes (2010) 2.36

Organ transplantation--how much of the promise has been realized? Nat Med (2005) 2.26

Prediction and pathogenesis in type 1 diabetes. Immunity (2010) 2.26

Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum (2013) 2.17

Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity (2013) 2.08

B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol (2007) 2.05

A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin. J Invest Dermatol (2012) 2.05

The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity (2006) 2.04

Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum (2005) 2.03

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02

Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes (2002) 2.01

Notch signaling augments T cell responsiveness by enhancing CD25 expression. J Immunol (2003) 1.95

Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells. Immunity (2008) 1.95

ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med (2007) 1.94

PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs. J Clin Invest (2006) 1.93

The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells. Immunity (2002) 1.89

Informed consent in a clinical trial of a novel treatment for rheumatoid arthritis. Arthritis Rheum (2003) 1.86

Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nat Med (2002) 1.84

Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A (2008) 1.83

A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) (2009) 1.82

Allograft rejection mediated by memory T cells is resistant to regulation. Proc Natl Acad Sci U S A (2007) 1.81

CTLA4Ig: bridging the basic immunology with clinical application. Immunity (2006) 1.75

Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med (2007) 1.73

Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med (2006) 1.67

Common variants in P2RY11 are associated with narcolepsy. Nat Genet (2010) 1.65

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum (2006) 1.64

Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J Immunol (2005) 1.62

The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. J Rheumatol (2007) 1.62

Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells. J Immunol (2005) 1.61

IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proc Natl Acad Sci U S A (2011) 1.61

Impaired T cell function in RANTES-deficient mice. Clin Immunol (2002) 1.60

Organ transplantation: halfway through the first century. J Am Soc Nephrol (2004) 1.59

Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study. Diabetes Care (2002) 1.59

Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol (2005) 1.58

Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J Clin Invest (2014) 1.58

Association of tumor necrosis factor alpha polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. Arthritis Rheum (2006) 1.55

The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J Exp Med (2005) 1.55

T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest (2014) 1.53

High-sensitivity detection and quantitative analysis of native protein-protein interactions and multiprotein complexes by flow cytometry. Sci STKE (2007) 1.51

Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol (2006) 1.51

New prospects for autoimmune disease therapy: B cells on deathwatch. Arthritis Rheum (2006) 1.51

The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest (2008) 1.50

Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity. J Exp Med (2005) 1.50

The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol (2003) 1.50

Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes (2006) 1.49

Tregs and transplantation tolerance. J Clin Invest (2004) 1.49

Vhlh gene deletion induces Hif-1-mediated cell death in thymocytes. Mol Cell Biol (2004) 1.48

An obligate cell-intrinsic function for CD28 in Tregs. J Clin Invest (2013) 1.46

MyD88 plays a critical T cell-intrinsic role in supporting CD8 T cell expansion during acute lymphocytic choriomeningitis virus infection. J Immunol (2008) 1.45

Analysis of the workforce and workplace for rheumatology and the research activities of rheumatologists early in their careers. Arthritis Rheum (2010) 1.45

Role of CXC chemokine receptor 3 pathway in renal ischemic injury. J Am Soc Nephrol (2006) 1.44

T cell expression of MyD88 is required for resistance to Toxoplasma gondii. Proc Natl Acad Sci U S A (2008) 1.43

Critical, but conditional, role of OX40 in memory T cell-mediated rejection. J Immunol (2006) 1.42

GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes. Diabetes (2004) 1.41

Mechanisms underlying blockade of allograft acceptance by TLR ligands. J Immunol (2008) 1.41

B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol (2008) 1.40

Functional avidity directs T-cell fate in autoreactive CD4+ T cells. Blood (2005) 1.39

Self-reactive human CD4 T cell clones form unusual immunological synapses. J Exp Med (2012) 1.38

Cutting edge: high molecular weight hyaluronan promotes the suppressive effects of CD4+CD25+ regulatory T cells. J Immunol (2007) 1.38

Hypoxia inducible factor 1 alpha regulates T cell receptor signal transduction. Proc Natl Acad Sci U S A (2005) 1.38

Defective activation of protein kinase C and Ras-ERK pathways limits IL-2 production and proliferation by CD4+CD25+ regulatory T cells. J Immunol (2006) 1.37

Cutting edge: T cell requirement for CD28 costimulation is due to negative regulation of TCR signals by PTEN. J Immunol (2006) 1.37

Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum (2006) 1.36

An update on regulatory T cells in transplant tolerance and rejection. Nat Rev Nephrol (2010) 1.35

Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc Natl Acad Sci U S A (2007) 1.35

Characterization of a Mycobacterium tuberculosis peptide that is recognized by human CD4+ and CD8+ T cells in the context of multiple HLA alleles. J Immunol (2004) 1.34

Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA (2012) 1.33

Alloreactive T cell responses and acute rejection of single class II MHC-disparate heart allografts are under strict regulation by CD4+ CD25+ T cells. J Immunol (2005) 1.32

Occupational risk factors for the development of systemic lupus erythematosus. J Rheumatol (2004) 1.31

Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med (2005) 1.30

Searching for borrelial T cell epitopes associated with antibiotic-refractory Lyme arthritis. Mol Immunol (2008) 1.30

Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States. Arthritis Rheum (2002) 1.29

CpG DNA inhibits CD4+CD25+ Treg suppression through direct MyD88-dependent costimulation of effector CD4+ T cells. Immunol Lett (2007) 1.29

CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-beta. J Immunol (2009) 1.28

Presentation of Toxoplasma gondii antigens via the endogenous major histocompatibility complex class I pathway in nonprofessional and professional antigen-presenting cells. Infect Immun (2007) 1.26

Animal models of human type 1 diabetes. Nat Immunol (2009) 1.26